These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25583727)

  • 1. Lung concentrations of ceftazidime administered by continuous versus intermittent infusion in patients with ventilator-associated pneumonia.
    Cousson J; Floch T; Guillard T; Vernet V; Raclot P; Wolak-Thierry A; Jolly D
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1905-9. PubMed ID: 25583727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of clinical cure rates in adults with ventilator-associated pneumonia treated with intravenous ceftazidime administered by continuous or intermittent infusion: a retrospective, nonrandomized, open-label, historical chart review.
    Lorente L; Jiménez A; Palmero S; Jiménez JJ; Iribarren JL; Santana M; Martín MM; Mora ML
    Clin Ther; 2007 Nov; 29(11):2433-9. PubMed ID: 18158083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia].
    Cousson J; Floch T; Vernet-Garnier V; Appriou M; Petit JS; Jovenin N; Lamiable D; Hoizey G
    Pathol Biol (Paris); 2005; 53(8-9):546-50. PubMed ID: 16023303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa.
    Lu Q; Yang J; Liu Z; Gutierrez C; Aymard G; Rouby JJ;
    Am J Respir Crit Care Med; 2011 Jul; 184(1):106-15. PubMed ID: 21474643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia.
    Boselli E; Breilh D; Rimmelé T; Poupelin JC; Saux MC; Chassard D; Allaouchiche B
    Intensive Care Med; 2004 May; 30(5):989-91. PubMed ID: 14985960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections.
    Benko AS; Cappelletty DM; Kruse JA; Rybak MJ
    Antimicrob Agents Chemother; 1996 Mar; 40(3):691-5. PubMed ID: 8851594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli.
    Lorente L; Lorenzo L; Martín MM; Jiménez A; Mora ML
    Ann Pharmacother; 2006 Feb; 40(2):219-23. PubMed ID: 16449546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung deposition of continuous and intermittent intravenous ceftazidime in experimental Pseudomonas aeruginosa bronchopneumonia.
    Girardi C; Tonnellier M; Goldstein I; Sartorius A; Wallet F; Rouby JJ;
    Intensive Care Med; 2006 Dec; 32(12):2042-8. PubMed ID: 16858611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia.
    Boselli E; Breilh D; Caillault-Sergent A; Djabarouti S; Guillaume C; Xuereb F; Bouvet L; Rimmelé T; Saux MC; Allaouchiche B
    J Antimicrob Chemother; 2012 May; 67(5):1207-10. PubMed ID: 22351682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intrapulmonary pharmacokinetics of antibiotics used to treat nosocomial pneumonia caused by Gram-negative bacilli: A systematic review.
    Heffernan AJ; Sime FB; Lipman J; Dhanani J; Andrews K; Ellwood D; Grimwood K; Roberts JA
    Int J Antimicrob Agents; 2019 Mar; 53(3):234-245. PubMed ID: 30472292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia.
    Boselli E; Breilh D; Saux MC; Gordien JB; Allaouchiche B
    Intensive Care Med; 2006 Dec; 32(12):2059-62. PubMed ID: 17039351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamics of doripenem in critically ill patients with ventilator-associated Gram-negative bacilli pneumonia.
    Jaruratanasirikul S; Wongpoowarak W; Kositpantawong N; Aeinlang N; Jullangkoon M
    Int J Antimicrob Agents; 2012 Nov; 40(5):434-9. PubMed ID: 22959555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial.
    Torres A; Zhong N; Pachl J; Timsit JF; Kollef M; Chen Z; Song J; Taylor D; Laud PJ; Stone GG; Chow JW
    Lancet Infect Dis; 2018 Mar; 18(3):285-295. PubMed ID: 29254862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empiric antibiotics pending bronchoalveolar lavage data in patients without pneumonia significantly alters the flora, but not the resistance profile, if a subsequent pneumonia develops.
    Thakkar RK; Monaghan SF; Adams CA; Stephen A; Connolly MD; Gregg S; Cioffi WG; Heffernan DS
    J Surg Res; 2013 May; 181(2):323-8. PubMed ID: 22906560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia.
    Boselli E; Breilh D; Rimmelé T; Guillaume C; Xuereb F; Saux MC; Bouvet L; Chassard D; Allaouchiche B
    Crit Care Med; 2008 May; 36(5):1500-6. PubMed ID: 18434883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Linezolid plasma and intrapulmonary concentrations in critically ill obese patients with ventilator-associated pneumonia: intermittent vs continuous administration.
    De Pascale G; Fortuna S; Tumbarello M; Cutuli SL; Vallecoccia M; Spanu T; Bello G; Montini L; Pennisi MA; Navarra P; Antonelli M
    Intensive Care Med; 2015 Jan; 41(1):103-10. PubMed ID: 25413377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration.
    Imberti R; Cusato M; Villani P; Carnevale L; Iotti GA; Langer M; Regazzi M
    Chest; 2010 Dec; 138(6):1333-9. PubMed ID: 20558557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of ceftazidime in serum and suction blister fluid during continuous and intermittent infusions in healthy volunteers.
    Mouton JW; Horrevorts AM; Mulder PG; Prens EP; Michel MF
    Antimicrob Agents Chemother; 1990 Dec; 34(12):2307-11. PubMed ID: 2088186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo efficacy of continuous infusion versus intermittent dosing of ceftazidime alone or in combination with amikacin relative to human kinetic profiles in a Pseudomonas aeruginosa rabbit endocarditis model.
    Robaux MA; Dube L; Caillon J; Bugnon D; Kergueris MF; Navas D; Le Conte P; Baron D; Potel G
    J Antimicrob Chemother; 2001 May; 47(5):617-22. PubMed ID: 11328773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia.
    Mimoz O; Rolland D; Adoun M; Marchand S; Breilh D; Brumpt I; Debaene B; Couet W
    Intensive Care Med; 2006 May; 32(5):775-9. PubMed ID: 16550370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.